Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Production of pseudotyped recombinant AAV virions

a technology of recombinant aav and virions, which is applied in the field of molecular biology, gene therapy, microbiology and virology, can solve the problems of inefficient methods, insufficient large-scale production of pseudotyped recombinant virions, and the preference of particular tissue of interest for delivery of conventional aav, etc., to achieve efficient, large-scale production of pseudotyped virions, and high purification and concentration of virion

Inactive Publication Date: 2007-01-18
SNYDER RICHARD O +12
View PDF3 Cites 77 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The invention is about creating reagents and methods for producing purified AAV2 vectors that can be used for gene therapy applications. The invention involves developing helper vectors that can be used to pseudotype AAV2 virions with other serotypes of AAV. The method involves using iodixanol and chromatography steps to purify the virions. The technical effect of this invention is the efficient and large-scale production of purified AAV2 virions with other serotypes of AAV. These virions can be used for gene therapy applications."

Problems solved by technology

Due to the broad host and tissue range, however, delivery of conventional AAV preferentially to a particular tissue of interest has been problematic.
These methods are inefficient and inadequate for large-scale production of pseudotyped recombinant virions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Production of pseudotyped recombinant AAV virions
  • Production of pseudotyped recombinant AAV virions
  • Production of pseudotyped recombinant AAV virions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0060] AAV helper plasmids were constructed by combining the ORF coding for the AAV2 Rep proteins and the ORF coding for capsid proteins of serotypes 1 and 5. The pACG2R1C helper plasmid was constructed by substituting the AAV1 cap ORF for AAV2 cap ORF in pACG2 (Li et al., J. Virol. 71:5236-5243, 1997) and a similar approach was applied to the pACG2R5C plasmid. Rep2cap1 and rep2cap5 helper cassettes were then subcloned into an Ad helper plasmid, pXYZ, constructed from pAdEasy. To construct pXYZ, several Ad genes (penton, core protein, hexon, and Ad DNA polymerase) were disrupted and the left hand end of the Ad genome was removed to eliminate the possibility of generating infectious Ad and Ad structural proteins (some of which are cytotoxic). The resultant plasmids pXYZ1 and pXYZ5 (FIG. 1) were used to pseudotype AAV2-ITR-containing expression cassettes into AAV1 and AAV5 capsids, respectively.

Construction of pXYZ1 and pXYZ5 Helper Plasmids

[0061] pXYZ Ad helpe...

example 2

Purification of rAAV1 and 5 Virions

[0076] Because AAV1 and AAV5 both lack significant binding to the heparin affinity resin used to purify rAAV2 virions, purification protocols were developed that use density gradient centrifugation followed by anion exchange or hydroxyapatite chromatography.

[0077] Following density gradient centrifugation, rAAV virions were purified by column chromatography. Three column resins were used: heparin-agarose, Q-sepharose, and hydroxyapatite. AAV2 virions bound heparin-agarose (FIGS. 6A and B), AAV5 virions bound hydroxyapatite, and AAV1, 2, and 5 virions bound Q-Sepaharose (FIGS. 3A and 4). rAAV2 virions eluted from heparin with 0.35M NaCl and rAAV5 virions eluted from hydroxyapatite with 0.2 M phosphate. AAV1, 2, and 5 eluted from Q-Sepharose in 0.5 M NaCl. As shown in FIG. 6A, virions produced were 99% pure with the three capsid proteins at the proper ratio of ˜1:1:20 for VP1:VP2:VP3. A combination of iodixanol step gradient followed by either affi...

example 3

ICA For rAAV and rcAAV

[0079] The infectious titer of rAAV was determined by measuring the ability of the virus to infect C12 cells expressing AAV2 rep and cap ORFs, unpackage, and replicate (FIG. 5A). In this assay, rep-cap expressing C12 cells were infected with serial dilutions of rAAV. To score the infecting viral particle it was amplified through viral DNA replication, whereupon the number of viral genomes reached several thousand per cell. This amplification was achieved by co-infecting the cell with a saturating amount of Ad5 to initiate rep and cap gene expression required for AAV DNA replication. The cells were then incubated for 40 hours, harvested, and transferred onto a nylon membrane and lysed. The immobilized viral DNA was hybridized with a transgene-specific probe and the cells infected with rAAV particles were scored as black dots following autoradiography (FIG. 5A).

[0080] WT AAV may contaminate vector preparations, and rcAAV may be formed during the production of r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012−1×1013 vector genomes / ml.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application claims the priority of U.S. provisional patent application No. 60 / 385,864 filed on Jun. 5, 2002.STATEMENT AS TO FEDERALLY SPONSORED RESEARCH [0002] This invention was made with United States government support under grant numbers NS36302, HL51811, DK58327, and HL59412 all awarded by the National Institutes of Health. The United States government may have certain rights in the invention.FIELD OF THE INVENTION [0003] The invention relates to the fields of molecular biology, gene therapy, microbiology and virology. More particularly, the invention relates to compositions and methods for producing and purifying recombinant Adeno-Associated Virus (rAAV) virions. BACKGROUND OF THE INVENTION [0004] AAV, a non-pathogenic, helper-dependent virus, is an attractive vector for gene therapy as it exhibits a wide host and tissue range and is able to replicate in cells from any species as long as there is a successful infection...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12P21/06C12N7/00C12N15/861C12N5/06C12N15/864
CPCC12N15/86C12N2840/20C12N2750/14143C12N2710/10322
Inventor SNYDER, RICHARD O.ZOLOTUKHIN, SERGIESAKAI, YOSHIHISABYRNE, BARRY J.POTTER, MARK R.ZOLOTUKHIN, IRINELOILER, SCOTTCHIODO, VINCE A.MUZYCZKA, NICHOLASHAUSWIRTH, WILLIAMFLOTTE, TERENCE R.BURGER, CORINNARODRIGUEZ, EDGARDO
Owner SNYDER RICHARD O
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com